The Humira comparative, and how about a bonus?, page-15

When you look at comparing RA to OA market suggest it's done on cost of burden of each respectively. This is a total cost to society rather than just medication sold in isolation.

If you google it you'll find some brilliant commissions research in both Aust and NZ. It has 100% relevance to the US, Canadian and EU market.

OA patients are currently offered very little to manage pain given most government and leading medical authorities guidance is now to avoid opioids unless under extreme circumstances and no more than 3 months.

Pain is the number 1 priority for most OA patients and it impacts up to 1/3 people in their lifetime. It is directly linked to an epidemic in obesity and cardiovascular disease which in turn is leading to very poor psychology health.

Health care for OA has major limitations given doctors are required to resort in most instances to encouraging their patients to losing weight and become more active. They know most won't sustain the required lifestyle change due to the pain itself. Moreover, once the hits breaking point very few patients are optimally conditioned for knee or hip replacement surgery with 30% dissatisfied with the eventual outcomes.

Paradigm's iPPS is looking to break the pain cycle with no SAE and with duration of effect. This alone should make it a first line treatment for many many doctors given they know what is being endured by so many. If we get DM then we have extreme upside but it won't be required for iPPS to become a leading drug for OA.

I'll post some references when I have a chance to some mind blowing government research papers that will highlight how well we're positioned to dominate the OA space. It'll be a win win win for us, governments and patients.